Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer

CLEVELAND--(BUSINESS WIRE)--Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials.
Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral.
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes.
Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes 'the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations.' Song adds, 'Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges.'
About Lubrizol
Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit www.lubrizol.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

26 minutes ago

• Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

Business Wire

32 minutes ago

• Business Wire

COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

Yahoo

34 minutes ago

• Yahoo

Warner Bros. Discovery (NasdaqGS:WBD) To Split After 60% Fall; Seeks Investors

Warner Bros. Discovery has announced its decision to split into two separate public companies, a major shift in strategy aiming to focus on streaming growth while housing underperforming cable channels separately. This decision follows a significant decline in stock value since the merger with Warner Media. Over the past month, the company's stock rose 14%, which might align with a broader market sentiment, also up during this period. Events such as Amazon Prime's partnership for early film screenings and new product launches like the "Harry Potter™ Pinball" might add incremental interest in the stock but are unlikely to have drastically influenced this change. We've discovered 1 weakness for Warner Bros. Discovery that you should be aware of before investing here. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent decision by Warner Bros. Discovery to split into two public companies may potentially affect its strategic plans and earnings forecasts. By focusing one entity on streaming and separating underperforming cable divisions, the aim is to enhance growth and stabilize revenue streams, particularly through Max's international subscriber growth. This structural change could lead to increased direct-to-consumer revenue, as efforts are made to reinforce industry leadership while addressing debt and cost challenges. Over the past year, Warner Bros. Discovery's total return, including share price gains and dividends, was 34.57%. However, when compared with the longer-term period, it underperformed the US Entertainment industry, which returned 62.4% over the same timeframe. Nonetheless, the company's shares did outpace the broader US market, which returned 11.2% during the last year. In terms of the recent 14% increase in share value in the past month, this movement provides context to the company's current position relative to analyst price targets. With the share price sitting at US$8.43, it remains approximately 36.7% below the consensus target of US$13.19. This discount suggests that investors may be waiting to see evidence of positive impacts on revenue and net earnings before aligning more closely with analyst expectations. Our comprehensive valuation report raises the possibility that Warner Bros. Discovery is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:WBD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data